Abstract
Noonan syndrome (NS), an autosomal dominant multisystem disorder, is caused by the dysregulation of the RAS-MAPK pathway and is characterized by short stature, heart defects, pectus excavatum, webbed neck, learning problems, cryptorchidism and facial dysmorphism. We here present the clinical and molecular characterization of a family with NS and multiple giant cell lesions (MGCLs). The proband is a 12-year-old girl with NS and MGCL. Her mother shows typical NS without MGCL. Whole-exome sequencing of the girl, her mother and her healthy maternal grand parents revealed a previously unobserved mutation in exon 5 of the PTPN11 gene (c.598 A>T; p.N200Y), transmitted from the mother to the proband. As no other modification in the RAS-MAPK pathway genes as related to Rasopathies was detected in the proband, this report demonstrates for the first time that a unique mutation affecting this, otherwise unaffected signaling route, can cause both NS and NS/MGCL in the same family. This observation further confirms that NS/MGCL is not a distinct entity but rather that MGCL represents a rare complication of NS. Moreover, the localization of the p.N200Y mutation suggests an alternative molecular mechanism for the excessive phosphatase activity of the PTPN11-encoded protein.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Mendez, H. M. & Opitz, J. M. Noonan syndrome: a review. Am. J. Med. Genet. 21, 493–506 (1985).
Noonan, J. A. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am. J. Dis. Child. 116, 373–380 (1968).
Roberts, A. E., Allanson, J. E., Tartaglia, M. & Gelb, B. D. Noonan syndrome. Lancet 381, 333–342 (2013).
Tartaglia, M., Zampino, G. & Gelb, B. D. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol. Syndromol. 1, 2–26 (2010).
Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H. et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29, 465–468 (2001).
Aoki, Y., Niihori, T., Banjo, T., Okamoto, N., Mizuno, S., Kurosawa, K. et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am. J. Hum. Genet. 93, 173–180 (2013).
Feng, G. S. Shp-2 tyrosine phosphatase: Signaling one cell or many. Exp. Cell. Res. 253, 47–54 (1999).
Stein-Gerlach, M., Wallasch, C. & Ullrich, A. SHP-2, SH2-containing protein tyrosine phosphatase-2. Int. J. Biochem. Cell B. 30, 559–566 (1998).
Neel, B. G., Gu, H. & Pao, L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends. Biochem. Sci. 28, 284–293 (2003).
Tartaglia, M., Kalidas, K., Shaw, A., Song, X., Musat, D. L., van der Burgt, I. et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am. J. Hum. Genet. 70, 1555–1563 (2002).
Blay, J. Y., El Sayadi, H., Thiesse, P., Garret, J. & Ray-Coquard, I. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann. Oncol. 19, 821–822 (2008).
Cassier, P. A., Gelderblom, H., Stacchiotti, S., Thomas, D., Maki, R. G., Kroep, J. R. et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 118, 1649–1655 (2012).
Tartaglia, M. & Gelb, B. D. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann. N. Y. Acad. Sci. 1214, 99–121 (2010).
Tidyman, W. E. & Rauen, K. A. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr. Opin. Genet. Dev. 19, 230–236 (2009).
Cohen, M. M. Jr. & Gorlin, R. J. Noonan-like/multiple giant cell lesion syndrome. Am. J. Med. Genet. 40, 159–166 (1991).
Beneteau, C., Cave, H., Moncla, A., Dorison, N., Munnich, A., Verloes, A. et al. SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions. Eur. J. Hum. Genet. 17, 1216–1221 (2009).
Acknowledgements
This work was supported by funds from the Strasbourg High Throughput Next Generation Sequencing facility (GENOMAX) and INSERM UMR_S1109.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supplementary Information accompanies the paper on Journal of Human Genetics website
Rights and permissions
About this article
Cite this article
Carapito, R., Paul, N., Untrau, M. et al. A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions. J Hum Genet 59, 57–59 (2014). https://doi.org/10.1038/jhg.2013.118
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/jhg.2013.118
